SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Press Releases
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
November 21, 2024
 · 
14 min read
Press Releases
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
November 5, 2024
 · 
20 min read
Press Releases
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
November 1, 2024
 · 
1 min read
Opioid health risk and medical crisis with a prescription painkiller addiction epidemic concept as a group of people running away from a dangerous falling bridge of pills as a medicine addict problem with 3D illustration elements.
FDA
5 Accelerated Approvals Gone Wrong
October 14, 2024
 · 
7 min read
 · 
Heather McKenzie
Press Releases
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
September 18, 2024
 · 
15 min read
Press Releases
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
September 18, 2024
 · 
16 min read
Press Releases
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
September 5, 2024
 · 
14 min read
Press Releases
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
August 6, 2024
 · 
20 min read
Press Releases
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
August 5, 2024
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the Jefferies Global Healthcare ConferenceFireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET
June 3, 2024
 · 
1 min read
Pharm Country
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 31, 2024
 · 
13 min read
Pharm Country
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 28, 2024
 · 
14 min read
Business
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 1, 2024
 · 
19 min read
Business
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
April 30, 2024
 · 
1 min read
Drug Development
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
April 18, 2024
 · 
13 min read
Business
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
April 18, 2024
 · 
13 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS